Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b-Reference-Cited by-同舟云学术

Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b

Published:2016-11 Issue:11 Volume:36 Page:635-643
ISSN:1079-9907
Container-title:Journal of Interferon & Cytokine Research
language:en
Short-container-title:Journal of Interferon & Cytokine Research

Author:

Flisiak Robert¹,Kawazoe Seiji²,Znoyko Olga³,Assy Nimer⁴,Gadano Adrian⁵,Kao Jia-Horng⁶,Lee Kwan-Sik⁷,Zwirtes Ricardo⁸,Portsmouth Simon⁸,Dong Yuping⁹,Xu Dong⁸,Kumada Hiromitsu¹⁰,Srinivasan Subasree⁸

Affiliation:

1. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.

2. Department of Hepatobiliary and Pancreatology, Saga Prefectural Hospital Koseikan, Saga, Japan.

3. Moscow State University of Medicine and Dentistry, Moscow, Russia.

4. Department of Liver, Ziv Medical Center and Bar-Ilan University, Safed, Israel.

5. Liver Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

6. Hepatitis Research Center, National Taiwan University, Taipei, Taiwan.

7. Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea.

8. Research and Development, Bristol-Myers Squibb, Inc., Wallingford, Connecticut.

9. Research and Development, Bristol-Myers Squibb, Inc., Princeton, New Jersey.

10. Department of Hepatology, Toranomon Hospital, Tokyo, Japan.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Cell Biology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/jir.2015.0173

Reference31 articles.

1. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

2. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C

3. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

4. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection

5. Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Membrane-proximal motifs encode differences in signaling strength between type I and III interferon receptors;Science Signaling;2023-10-10

2. Synthetic Heterodimers of Type III Interferon Receptors Require TYK2 for STAT Activation;Journal of Interferon & Cytokine Research;2023-09-01

3. Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions;The Journal of Immunology;2022-01-15

4. The Role of Type III Interferons in Human Disease;Clinical and Investigative Medicine;2021-06-14

5. Type III interferons: Balancing tissue tolerance and resistance to pathogen invasion;Journal of Experimental Medicine;2019-12-05